Ying Gong

Dr. Gong is the Chief Business Officer of GV20. She is an experienced strategist, drug developer and leader. Her extensive biopharmaceutical experience encompasses multiple therapeutic areas, drug modalities, R&D stages, and functions. Most recently, Dr. Gong served as Project Team Leader, Oncology at Genentech, where she led drug development programs from late-stage research to clinical proof-of-concept as well as business development projects. She also served as Senior Director of Portfolio Strategy and Planning and made significant contributions in shaping Genentech's overall R&D strategy. Prior to that, she held roles in medical affairs, market access, global product strategy, and market planning at Genentech and Roche, and worked on a broad range of projects including new indication launches of Perjeta® and Avastin®. She started her career in industry as a management consultant at Bain & Company.

Dr. Gong earned a Ph.D. in Biochemistry and Molecular Biophysics from the California Institute of Technology, and an M.A. in Molecular Genetics from Smith College. She did her undergraduate studies at Peking University.